Phio Pharmaceuticals Corp. announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer. NK cells are the body's first line of defense against cancer.

Unlike T cells, NK cells can recognize and kill tumor cells without prior exposure. Incorporating INTASYL's RNAi treatment into ex vivo NK cell expansion protocols prior to adoptive cell therapy (ACT) is a strategy to reduce the expression of inhibitory proteins such as TIGIT or CBL-B to improve anti-tumor response.